

# Gene Wallenstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5450098/publications.pdf>

Version: 2024-02-01

6  
papers

2,133  
citations

1477746

6  
h-index

1872312

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

1511  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. <i>Lancet, The</i> , 2013, 381, 451-460.	6.3	610
2	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013, 65, 559-570.	6.7	481
3	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	2.0	381
4	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339
5	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2012, 64, 970-981.	6.7	293
6	Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. <i>International Journal of Rheumatology</i> , 2017, 2017, 1-15.	0.9	29